BBLG (Bone Biologics) 5-Year EBITDA Growth Rate: 62.30% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BBLG Bone Biologics Corp BBLG
26 GF Score
Price $0.57
! 1 Warning Sign
View Full Analysis

What is Bone Biologics 5-Year EBITDA Growth Rate?

Bone Biologics BBLG +1.86% 26 5-Year EBITDA Growth Rate is 62.30% as of Jun. 2026. GuruFocus rates BBLG with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Bone Biologics's EBITDA per Share for the three months ended in Jun. 2026 was $-0.45.

During the past 3 years, the average EBITDA Per Share Growth Rate was 81.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 62.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 53.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bone Biologics was 81.80% per year. The lowest was 4.60% per year. And the median was 46.00% per year.

Bone Biologics  (NAS:BBLG) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Bone Biologics 5-Year EBITDA Growth Rate Related Terms

BBLG vs SCNI, ATXI, PTIX: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Bone Biologics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bone Biologics 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bone Biologics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Bone Biologics's 5-Year EBITDA Growth Rate falls into.


BBLG
26GF Score
Bone Biologics Corp BBLG
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bone Biologics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 62.30% mean?
Bone Biologics (BBLG) has a 5-Year EBITDA Growth Rate of 62.30% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Bone Biologics and its competitors.
Is Bone Biologics' 5-Year EBITDA Growth Rate too high?
Bone Biologics' current 5-Year EBITDA Growth Rate is 62.30%. Overall, Bone Biologics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Bone Biologics' 5-Year EBITDA Growth Rate compare to SCNI and ATXI?
Bone Biologics' 5-Year EBITDA Growth Rate of 62.30% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Bone Biologics and its competitors. Bone Biologics's current 5-Year EBITDA Growth Rate is 62.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bone Biologics stock overvalued right now?
Bone Biologics (BBLG) has a current 5-Year EBITDA Growth Rate of 62.30%. The current 5-Year EBITDA Growth Rate is 62.30%. Bone Biologics' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Bone Biologics (BBLG), the current 5-Year EBITDA Growth Rate is 62.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bone Biologics Business Description

Address 2 Burlington Woods Drive, Suite 100, Burlington, MA, USA, 01803
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
26GF Score

Get the complete analysis for BBLG

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.57
Price